Stocktoria

Trevi Therapeutics, Inc. TRVI

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-05-07

Trevi Therapeutics, Inc. statistics & valuation

Market cap$2.6B
P / B14.1×
Return on equity-23.3%
Return on capital-26.9%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20182019202020212022202320242025
Operating margin (%)
20182019202020212022202320242025
Return on equity (%)
-47.80% -120.10% -198.80% -27.10% -35.20% -48.10% -23.30% 20182019202020212022202320242025
Shares outstanding
438600 17.8M 18.5M 28.5M 64.5M 99.0M 102.0M 134.7M 20182019202020212022202320242025
Net debt ($)
20182019202020212022202320242025
Share buybacks ($)
20182019202020212022202320242025
Return on assets (%)
-195.20% -43.40% -69.50% -88.20% -23.70% -32.50% -43.20% -22.10% 20182019202020212022202320242025
Free cash flow margin (%)
20182019202020212022202320242025
Debt / equity (×)
20182019202020212022202320242025
EPS ($)
-$1.49 -$0.45 -$0.29 -$0.47 -$0.32 20182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Return on assets-22.1%-43.2%-32.5%-23.7%-88.2%-69.5%-43.4%-195.2%
Return on equity-23.3%-48.1%-35.2%-27.1%-198.8%-120.1%-47.8%18.8%
Current ratio19.6610.4115.039.152.988.3311.453.30

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.